
 
 
 
 
 
 
 
 
   
   
 1. An anti-IL13 receptor .alpha.1 antibody, which has an activity of inhibiting a cell response by IL13.  
 
     
 2. An anti-IL13 receptor .alpha.1 antibody, characterized in that the anti-IL13 receptor .alpha.1 antibody has an activity of inhibiting a cell response by IL13 but does not inhibit a cell response by IL4.  
 
     
 3. The anti-IL13 receptor .alpha.1 antibody, according to Claim 1 or 2, wherein the anti-IL13 receptor al antibody is bound to an IL13 receptor .alpha.1 at a dissociation constant of at least 10 nM.  
 
     
 4. The anti-IL13 receptor .alpha.1 antibody, according to any one of Claims 1 to 3, wherein the cell response by IL13 is a cell proliferation of TF-1 cells, and the activity of inhibiting the cell response by IL13 is at least one activity selected from the group consisting of (a-1) to (a-3) below: (a-1) an antibody concentration required for shifting a dose-response curve of IL13 in the cell response by IL13 toward a twice higher concentration is 10 µg/mL or less; (a-2) an IC50 against the cell response in the presence of IL13 at a concentration of 1 ng/mL is 10 µg/mL or less; and (a-3) an antibody concentration of 10 ug/mL inhibits 50% or more of the cell response in the presence of IL13 at a concentration of 1 ng/mL.  
 
     
 5. The anti-IL13 receptor al antibody, according to any one of Claims 1 to 4, wherein the anti-IL13 receptor .alpha.1 antibody is a monoclonal antibody.  
 
     
 6. The anti-IL13 receptor .alpha.1 antibody, according to any one of Claims 1 to 5, characterized in that the anti-IL13 receptor .alpha.1 antibody has a heavy chain variable region selected from the group consisting of (a) to (c) below: (a) a heavy chain variable region characterized by having a first complementarity determining region consisting of an amino acid sequence described in SEQ ID NO: 1, a second complementarity determining region consisting of an amino acid sequence described in SEQ ID NO: 2, and a third complementarity determining region consisting of an amino acid sequence described in SEQ ID NO: 3; (b) a heavy chain variable region characterized by having a first complementarity determining region consisting of an amino acid sequence described in SEQ ID NO: 6, a second complementarity determining region consisting of an amino acid sequence described in SEQ ID NO: 7, and a third complementarity determining region consisting of an amino acid sequence described in SEQ ID NO: 8; and (c) a heavy chain variable region characterized by having a first complementarity determining region consisting of an amino acid sequence described in SEQ ID NO: 12, a second complementarity determining region consisting of an amino acid sequence described in SEQ ID NO: 13, and a third complementarity determining region consisting of an amino acid sequence described in SEQ ID NO: 14.  
 
     
 7. The anti-IL13 receptor .alpha.1 antibody, according to Claim 6, characterized by comprising a light chain variable region having: a first complementarity determining region consisting of one amino acid sequence selected from the group consisting of amino acid sequence of SEQ ID NO: 4, amino acid sequence of SEQ ID NO: 9, and amino acid sequence of SEQ ID NO: 15; a second complementarity determining region consisting of one amino acid sequence selected from the group consisting of amino acid sequence of SEQ ID NO: 5, amino acid sequence of SEQ TD NO: 10, and amino acid sequence of SEQ ID NO: 16; and a third complementarity determining region consisting of one amino acid sequence selected from the group consisting of amino acid sequence of SEQ ID NO: 11 and amino acid sequence of SEQ ID NO: 17.  
 
     
 8. An antibody, which is produced by hybridoma F997-20-1, hybridoma F997-13-1, or hybridoma F997-10-1.  
 
     
 9. The anti-IL13 receptor .alpha.1 antibody according to any one of Claims 1 to 7, wherein the anti-IL13 receptor .alpha.1 antibody is a humanized antibody.  
 
     
 10. The anti-IL13 receptor al antibody according to Claim 9, wherein the humanized antibody comprises a human chimeric antibody.  
 
     
 11. The antibody according to Claim 10, wherein the human chimeric antibody is a human chimeric antibody consisting of: the heavy chain variable region and the light chain variable region of the antibody according to any one of Claims 1 to 7; and a heavy chain constant region and a light chain constant region of a human antibody.  
 
     
 12. The antibody according to Claim 10, wherein amino acid sequences of the heavy chain variable region and the light chain variable region are the same as amino acid sequences of a heavy chain variable region and a light chain variable region of an antibody produced by hybridoma F997-20-1, hybridoma F997-13-1, or hybridoma F997-10-1.  
 
     
 13. The anti-IL13 receptor al antibody according to Claim 9, wherein the humanized antibody comprises a human complementarity determining region grafted antibody.  
 
     
 14. The antibody according to Claim 13, wherein the human complementarity determining region grafted antibody is a human complementarity determining region grafted antibody consisting of: the heavy chain complementarity determining region and the light chain complementarity determining region of the antibody according to any one of Claims 1 to 7; and a heavy chain constant region, a light chain constant region, and a framework region of a human antibody.  
 
     
 15. The antibody according to Claim 14, wherein amino acid sequences of the heavy chain complementarity determining region and the light chain complementarity determining region have the same amino acid sequences as amino acid sequences of a heavy chain complementarity determining region and a light chain complementarity determining region of an antibody produced by hybridoma F997-20-1, hybridoma F997-13-1, or hybridoma F997-10-1.  
 
     
 16. The anti-IL13 receptor al antibody according to any one of Claims 1 to 7, wherein the anti-IL13 receptor a1 antibody is a human antibody obtained from a human antibody phage library or a human antibody-producing transgenic animal.  
 
     
 17. An anti-IL13 receptor a1 antibody fragment, comprising a part of the antibody according to any one of Claims 1 to 8 with an activity of inhibiting a cell response by IL13.  
 
     
 18. A hybridoma, which produces the antibody according to any one of Claims 1 to 7.  
 
     
 19. A hybridoma F997-20-1, hybridoma F997-13-1, or hybridoma F997-10-1.  
 
     
 20. A method of detecting an IL13 receptor .alpha.1 in a test sample using the antibody or the antibody fragment according to any one of Claims 1 to 17.  
 
     
 21. A method of inhibiting an action of IL13 to an IL13 receptor-expressing cell using the antibody or the antibody fragment according to any one of Claims 1 to 17.  
 
   
 
 
 
 
 
 
 
 
